Dataset Information

Pulmonary and Renal Long COVID at Two-year Revisit

ABSTRACT: To outline the temporal changes of long COVID, we profiled serum proteomes (dataset SP2) and urine proteomes (dataset UP2). The SP2 were measured for 37 patients during the disease (T1), the convalescence (T2), and at the 1-year revisit (T3); the UP2 were measured for 28 patients during the disease (T1) and at the revisit (T3). An equivalent number of healthy controls were added to each dataset. A validation cohort of 15 patients were further recruited during day 397 (386-487) to verify the unity of the prioritized serum proteins in predicting long COVID after one year.

ORGANISM(S): Homo Sapiens

SUBMITTER: Tiannan Guo

PROVIDER: PXD027557 | iProX | Tue Jun 04 00:00:00 BST 2024

REPOSITORIES: iProX

ACCESS DATA

Publications

Pulmonary and renal long COVID at two-year revisit.

Wang Jing J Liang Xiao X Zheng Yufen Y Zhu Yi Y Zhou Kai K Wu Xiaomai X Sun Rui R Hu Yifan Y Zhu Xiaoli X Chi Hongbo H Chen Shanjun S Lyu Mengge M Xie Yuting Y Yi Xiao X Liu Wei W Cai Xue X Li Sainan S Zhang Qiushi Q Wu Chunlong C Shi Yingqiu Y Wang Donglian D Peng Minfei M Zhang Ying Y Liu Huafen H Zhang Chao C Quan Sheng S Kong Ziqing Z Kang Zhouyang Z Zhu Guangjun G Zhu Hongguo H Chen Shiyong S Liang Junbo J Yang Hai H Pang Jianxin J Fang Yicheng Y Chen Haixiao H Li Jun J Xu Jiaqin J Guo Tiannan T Shen Bo B

iScience 20240621 7

This study investigated host responses to long COVID by following up with 89 of the original 144 cohorts for 1-year (<i>N</i> = 73) and 2-year visits (<i>N</i> = 57). Pulmonary long COVID, characterized by fibrous stripes, was observed in 8.7% and 17.8% of patients at the 1-year and 2-year revisits, respectively, while renal long COVID was present in 15.2% and 23.9% of patients, respectively. Pulmonary and renal long COVID at 1-year revisit was predicted using a machine learning model based on c ...[more]

PMID: 39055942

Similar Datasets

Project description:Background. COVID-19-induced neurological disease is a growing concern. Here we provide a comprehensive clinical, molecular, and neuroimaging investigation of patients presenting neurological symptoms to investigate underlying processes. Methods. We performed a detailed systematized clinical, laboratory, and neuroimaging (CT/MRI) data analysis from 35 mild to severe Brazilian COVID-19 hospitalised patients with clinical indications for cerebrospinal fluid (CSF) exam. In patients' CSF, we measured interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α) and the Alzheimer's disease-associated biomarkers amyloid-beta (Aβ)1-40, Aβ1-42, Tau and pTau181 levels (n=31-35). In addition, CSF proteomics and the search for SARS-CoV-2 spike protein presence using shotgun and targeted multiple reaction monitoring liquid-chromatography/mass-spectrometry were performed (n=16). We further evaluated a 29-cytokine panel in patients’ blood (n=16). An electronic questionnaire was conducted one-year post-hospitalisation (n=19, 63.3%). Findings. COVID-19 patients presented heterogeneous clinical and neurological features, including encephalopathy, encephalitis, and neuromuscular syndromes, despite low pulmonary burden. Patients showed increased circulating cytokines and CSF IL-6 and TNF-α levels compared to controls. Alzheimer’s disease-related biomarkers were unaltered compared to controls. COVID-19 altered CSF proteomic pathways associated to complement and coagulation cascades, immune-inflammatory, metabolism and amyloidosis. We found no traces of spike protein in patients’ CSF. Severe patients presented more pronounced neuroimaging alterations, altered CSF levels of IL-6, Tau, and Aβ-species compared to mild patients. Peripheral inflammation markers correlated with CSF IL-6 and Tau-species levels. Finally, in a one-year post-COVID survey, survivors were not recovered entirely (12/19) and reported confusion or memory/attention deficits (13/19). Interpretation. COVID-19 induces a broad spectrum of neurological presentations associated with changes in central nervous system (CNS) inflammatory and neurodegenerative molecular and structural biomarkers that correlate with systemic inflammation and disease severity. Given that neurological symptoms persist up to one-year post-COVID, our results urge us to investigate whether systemic, and CNS molecular changes are permanent or alleviated so that COVID-19 patients with lingering symptoms are adequately treated.

Dataset Information

Pulmonary and Renal Long COVID at Two-year Revisit

Publications

Pulmonary and renal long COVID at two-year revisit.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets